El interés en corto de Prelude Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Prelude Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Prelude Therapeutics (NASDAQ:PRLD) Bolsa, Informe de interés en corto

Prelude Therapeutics

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Lattice Semiconductor sorprende con un alza del 14,7% en el premercado. Descubre qué otras acciones están en movimiento.

Acciones de Lattice Semiconductor (LSCC) suben un 15%; 20 acciones que se mueven en el premercado

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics Inc

French President Emmanuel Macron has rejected the proposal by President Donald Trump to convert Gaza into a real estate project. Macron emphasized the need for respect for Palestinians and their Arab neighbors.
What Happened: Macron, in a CNN <a href="https://edition.cnn.com/2025/02/11/europe/macron-trump-gaza-real-estate-intl/index.html">interview</a>, stressed that the Gaza issue requires a political solution rather than a real estate one. He criticized the idea of displacing 2 million Gazans, stating, &#8220;You cannot say to 2 million people, &#8216;okay, now guess what? You will move.'&#8221;
&#8220;The right answer is not a real estate operation, this is a political operation,&#8221; said the French president.
Trump&#8217;s proposal, which has sparked controversy, involves relocating Palestinians from Gaza to Egypt and Jordan, while the U.S. takes long-term ownership of the enclave. He envisions transforming Gaza into a &#8220;Middle Eastern Riviera.&#8221;
Macron has consistently disagreed with Israeli Prime Minister Benjamin Netanyahu over Israel&#8217;s military operations in Gaza and Lebanon. In October 2024, France suspended arms exports to the Israel Defense Forces, urging other nations to follow suit.
Macron&#8217;s comments come amid a wave of international criticism, including from the United Nations and Spain, against Trump&#8217;s plans. The proposal has also sparked plans for redevelopment of Gaza by far-right settler groups in Israel, which would be illegal under international law.
Read Next: <a href="https://www.benzinga.com/news/global/25/02/43643471/trump-administration-secures-release-of-cannabis-prisoner-marc-fogel-from-14-year-russian-sentence">Trump Administration Secures Release Of Cannabis Prisoner Marc Fogel From 14-Year Russian Sentence</a>
Why It Matters: Trump&#8217;s proposal to &#8220;take over the Gaza Strip,&#8221; level it, and rebuild the area after Palestinians are sent elsewhere has been <a href="https://in.benzinga.com/news/25/02/43503385/trumps-gaza-plan-for-seaside-resort-faces-global-pushback">widely rejected</a> by world leaders. They argue that moving nearly 2 million Palestinians from Gaza is tantamount to ethnic cleansing.
Arab foreign ministers have also&nbsp;<a href="https://www.benzinga.com/markets/equities/25/02/43420541/arab-nations-reject-trumps-controversial-gaza-plan-heres-why">rejected</a>&nbsp;Trump's suggestion to transfer&nbsp;Palestinians from Gaza to neighboring&nbsp;Egypt and Jordan, calling it a destabilizing move that would threaten peace in the region.
Despite the global pushback, Trump, in a White House meeting with Jordan's King Abdullah, reiterated his threat that the U.S. will take control of the Gaza Strip and move the Palestinians living there to either Jordan or Egypt or somewhere else, as <a href="https://in.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">reported</a>.
Photo by Frederic Legrand &#8211; COMEO on Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Emmanuel Macron Rejects Trump's Plan Of Turning Gaza Into A Resort: 'The Right Answer Is Not A Real Estate Operation'

Anthropic, a leading AI company <a href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch">backed by Amazon</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NYSE">AMZN</a>) and <a href="https://www.benzinga.com/government/24/10/41528255/googles-2b-investment-in-anthropic-under-scrutiny-uk-opens-competition-inquiry">Google</a>, is reportedly having a seemingly contradictory stance on artificial intelligence. While the company actively promotes AI use in the workplace and develops AI-driven hiring tools, it has a strict rule for job seekers: do not use AI when applying for their positions.
<h2 class="wp-block-heading">The Double Standard</h2>
As an individual noticed and Futurism reported on, Anthropic's job application form explicitly states:
&#8220;While we encourage people to use AI systems during their role to help them work faster and more effectively, please do not use AI assistants during the application process. We want to understand your personal interest in Anthropic without mediation through an AI system, and we also want to evaluate your non-AI-assisted communication skills.&#8221;
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
The company profits from AI-powered hiring processes yet restricts candidates from using the same tools to improve their chances in an increasingly competitive job market. Meanwhile, AI is being widely adopted across hiring processes, with 98.4% of Fortune 500 companies using AI to filter applications and 43% of companies either using or planning to use AI for interviews, according to Jobscan.&nbsp;
<h2 class="wp-block-heading">Anthropic's AI Ambitions</h2>
Anthropic is at the forefront of AI development, <a href="https://www.benzinga.com/news/24/06/39426605/google-amazon-backed-openai-rival-anthropic-unveils-claude-3-5-sonnet-its-most-powerful-ai-yet">competing with OpenAI</a> and other major players. The company recently saw its annualized revenue surge to $1 billion, a tenfold increase from the previous year. It is also reportedly <a href="https://www.benzinga.com/25/01/43127416/anthropic-gains-big-with-google-backing-aiming-for-60-billion-valuation-and-surging-ai-revenue">securing $2 billion in funding</a>, which could triple its valuation to $60 billion.
Backed by Amazon's $8 billion investment and Google's recent $1 billion contribution, Anthropic is pushing forward with AI advancements. CEO Dario Amodei <a href="https://www.benzinga.com/markets/25/01/43094410/jeff-bezos-backed-anthropic-ceo-predicts-ai-will-surpass-human-intelligence-by-2027-but-warns-to-watch-out-for-negative-consequences">has predicted</a> that AI could surpass human intelligence within two to three years. He recently stated that Artificial General Intelligence—AI with human-level capabilities—could emerge by 2026 or 2027, barring setbacks like data shortages, GPU production issues, or scalability problems.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
While AI companies like Anthropic push for rapid advancements, they also set rules that seem to favor employers over job seekers. The rise of AI-driven hiring has already overwhelmed recruiters, leading to a cycle where companies turn to AI to sort through AI-generated applications.
Anthropic's policy highlights a growing concern. AI is being used to reshape the job market, but workers are being told they can't use it to compete. As both sides of hiring increasingly rely on AI, critics argue that companies must set fair and transparent standards—or risk creating a system where only employers benefit from AI's efficiencies.
For now, if you're applying to Anthropic, leave AI out of it. But once you're hired, feel free to use it all you want.
Read Next:
<ul>
<li>Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

AMZN

Amazon And Google-Backed AI Firm Anthropic Urges Job Seekers: Please Don't Use AI To Apply Here

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 20 years by 2.35% on an annualized basis producing an average annual return of 10.76%. Currently, Humana has a market capitalization of $30.99 billion. 
Buying $100 In HUM: If an investor had bought $100 of HUM stock 20 years ago, it would be worth $764.30 today based on a price of $257.34 for HUM at the time of writing.
<h3>Humana's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739317568_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Humana Stock In The Last 20 Years

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has outperformed the market over the past 20 years by 28.85% on an annualized basis producing an average annual return of 37.26%. Currently, NVIDIA has a market capitalization of $3.26 trillion. 
Buying $100 In NVDA: If an investor had bought $100 of NVDA stock 20 years ago, it would be worth $62,469.62 today based on a price of $133.02 for NVDA at the time of writing.
<h3>NVIDIA's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739316646_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVDA

$100 Invested In NVIDIA 20 Years Ago Would Be Worth This Much Today

<a href="https://www.benzinga.com/startups/25/01/43391017/2-trillion-by-2026-elon-musks-ambitious-push-to-reinvent-government-spending-with-silicon-valley-powerhouses">Elon Musk</a> isn't worried about Donald Trump stopping the rise of electric cars. In fact, he thinks it's impossible. "At this point, I think that sustainable transport is inevitable," Musk told investors.&nbsp;
Musk compared the shift to EVs to the transition from horse-drawn carriages to automobiles. "Even if you were the biggest horse advocate on Earth, you couldn't stop the advent of the automobile. And you can't stop the advent of electric cars," he said on a call late last month to discuss Tesla's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) latest quarterly results.&nbsp;&nbsp;
The biggest hurdle for EVs used to be range, but Musk says that's no longer an issue. With more charging infrastructure and better battery technology, people aren't as hesitant to switch. Still, the political scene is shifting, and some wonder what that means for Tesla and the industry as a whole.&nbsp;&nbsp;
Don't Miss:
<ul>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
One of Trump's first moves in office was to undo Joe Biden's goal of having 50% of new car sales be electric by 2030. He also wants to get rid of the federal EV tax credit, which gives buyers up to $7,500 in incentives.&nbsp;
That could make EVs a harder sell, but Musk isn't too concerned. In fact, he's actually in favor of ending those subsidies.&nbsp;
"Take away the subsidies. It will only help Tesla," <a href="https://x.com/elonmusk/status/1813112958157005259?lang=en">he said on X </a>last July. His argument? Tesla has already built a strong EV business, while other automakers still rely on incentives to stay competitive.&nbsp;&nbsp;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
That doesn't mean everything is smooth sailing for Tesla. According to Electrive, EV sales in the U.S. grew by only 7.3% in 2024, reaching 1.3 million units. That's just a slight bump from 7.8% to 8.1% of total car sales. Meanwhile, Tesla's own sales dropped by 5.6% to 633,762 vehicles—their first annual decline in over a decade.&nbsp;&nbsp;
But Musk believes Tesla's real edge isn't just in electric cars; it's in self-driving technology. "There is a path where Tesla is worth more than the next top five car companies combined&#8230; and that is overwhelmingly due to autonomous vehicles and autonomous humanoid robots," he said on the Jan. 30 earnings call.&nbsp;&nbsp;&nbsp;
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Tesla is also making adjustments based on new policy changes. For example, the company had planned to expand into Mexico, but Musk recently put that on hold after <a href="https://www.benzinga.com/startups/25/02/43493701/fed-chair-jerome-powell-faces-trumps-pressure-the-president-cant-fire-me-as-interest-rates-hold-steady-at-4-25-4-5">Trump </a>suggested heavy tariffs on Mexican-made cars. "Trump has said that he will put heavy tariffs on vehicles produced in Mexico, so it doesn't make sense to invest in Mexico," Musk said on a separate earnings call in July amid the 2024 presidential campaign.&nbsp;
Despite these challenges, Tesla isn't slowing down. The company is rolling out a driverless ride-hailing service in Austin within the next six months and is on track to produce autonomous "cybercabs" by 2026. It's also planning to unveil a working prototype of their Optimus humanoid robot in 2025.&nbsp;&nbsp;
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Startups

TSLA

Elon Musk: 'You Can't Stop The Advent Of Electric Cars'—Says EV Success Is As Inevitable As Cars Replacing Horses

Jones Trading analyst Jason Weaver maintains Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) with a Buy and maintains $12.5 price target.

Price Target

Analyst Ratings

RITM

Jones Trading Maintains Buy on Rithm Capital, Maintains $12.5 Price Target

Barrington Research analyst Gary Prestopino maintains Liquidity Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDT#NASDAQ">LQDT</a>) with a Outperform and maintains $40 price target.

LQDT

Barrington Research Maintains Outperform on Liquidity Services, Maintains $40 Price Target

Offerings

Flowers Foods Prices Public Offering Of $500M Of 5.750% Senior Notes Due 2035 And $300M Of 6.200% Senior Notes Due 2055

Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) has outperformed the market over the past 5 years by 5.19% on an annualized basis producing an average annual return of 17.64%. Currently, Baker Hughes has a market capitalization of $46.70 billion. 
Buying $1000 In BKR: If an investor had bought $1000 of BKR stock 5 years ago, it would be worth $2,143.31 today based on a price of $47.19 for BKR at the time of writing.
<h3>Baker Hughes's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739313918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Baker Hughes Stock In The Last 5 Years

Macquarie analyst Steve Koenig maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Outperform and maintains $200 price target.

DDOG

Macquarie Maintains Outperform on Datadog, Maintains $200 Price Target

HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.11) by 109.09 percent. This is a 112.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $29.23 million which beat the analyst consensus estimate of $26.50 million by 10.30 percent. This is a 6.47 percent decrease over sales of $31.25 million the same period last year.

Earnings

Earnings Beats

HIVE

HIVE Digital Technologies Q3 EPS $0.01 Beats $(0.11) Estimate, Sales $29.23M Beat $26.50M Estimate

Hexcel Prices Offering Of $300M Of Unsecured 5.875% Senior Notes Due 2035

Spire Global Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares are sinking in Tuesday&#8217;s after-hours session after it filed a c<a href="https://www.benzinga.com/news/asset-sales/24/11/41944207/spire-global-soars-on-heels-of-241-million-sale-of-maritime-business-plans-debt-payoff">omplaint against Kpler Holding</a>.
What Happened: In a new filing released after the market close on Tuesday, Spire Global announced that it filed a complaint in the Delaware Court of Chancery alleging Kpler failed to close on the <a href="https://www.benzinga.com/news/asset-sales/24/11/41944207/spire-global-soars-on-heels-of-241-million-sale-of-maritime-business-plans-debt-payoff">acquisition of Spire&#8217;s maritime business</a>.
Spire Global entered into a purchase agreement with Kpler in November to sell its maritime business for a cash payment based on an enterprise value of $233.5 million. The company said at the time that it expected the transaction to close in the first quarter. 
Spire Global said it believes all conditions in the purchase agreement have been satisfied or could be satisfied. The company also noted that Kpler agreed to "use best efforts, and to take any and all actions necessary&#8221; to consummate the transaction.
&#8220;The Company believes that Buyer's failure to close is not consistent with the terms of the Purchase Agreement, which do not give Buyer the option to delay closing once all closing conditions have been met,&#8221; Spire Global said in the filing.
See Also: <a href="https://www.benzinga.com/news/earnings/25/02/43641962/lyft-q4-earnings-revenue-beat-gross-bookings-up-15-new-buyback-our-biggest-competition-is-inertia">Lyft Q4 Earnings: Revenue Beat, Gross Bookings Up 15%, New Buyback — &#8216;Our Biggest Competition Is Inertia&#8217;</a>
As a result, Spire Global asked the courts to order Kpler to satisfy the purchase agreement obligations and close the deal.
&#8220;There is no assurance as to what action the Delaware Court of Chancery will take with respect to the proceeding initiated by the Company and there is no assurance as to whether or not the Transactions will be consummated on the terms contemplated or at all,&#8221; the company said.
Price Action: <a href="http://benzinga.com/quote/spir">Spire Global shares</a> were down 43.8% at $11.15 in Tuesday&#8217;s after-hours session at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">Trump Says We Will &#8216;Take Gaza&#8217; And &#8216;Cherish It&#8217; In White House Meeting With Jordan&#8217;s King Abdullah</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

SPIR

Spire Global Stock Is Plunging After Hours: What's Going On?

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 20 years by 1.28% on an annualized basis producing an average annual return of 9.69%. Currently, Travelers Companies has a market capitalization of $54.92 billion. 
Buying $1000 In TRV: If an investor had bought $1000 of TRV stock 20 years ago, it would be worth $6,299.71 today based on a price of $242.35 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739313152_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Travelers Companies 20 Years Ago Would Be Worth Today

Lifeway was an early investor in Simple Foods in 2015 and since that time, the Company has already realized a $1.5 million gain in 2019, bringing the total expected net proceeds to Lifeway of approximately $6.5 million.

LWAY

Lifeway Foods Expects To Realize Approximately $5M Of Net Profit Due To Recently Announced Sale Of Simple Foods To Flowers Foods

Marc Fogel, who <a href="https://www.benzinga.com/markets/cannabis/22/06/27780092/russia-sentences-60-something-former-us-diplomat-to-14-years-for-cannabis-possession" target="_blank" rel="noreferrer noopener">was sentenced to 14 years</a> in a Russian penal colony after his 2021 arrest in Moscow for possessing medical marijuana, is coming home.
The White House announced Tuesday, per various news outlets, that it had negotiated Fogel's release.
White House national security adviser Michael Waltz said that Steve Witkoff, President Donald Trump&#8216;s special envoy to the Middle East, was leaving Russian airspace with Fogel, who was declared "wrongfully detained" by President Joe Biden shortly before he left the White House.
Waltz said <a href="https://www.benzinga.com/markets/cannabis/24/08/40111778/russia-prisoner-swap-senators-demand-inclusion-of-cannabis-prisoner-marc-fogel-mom-takes-antony-">Fogel</a>, who previously worked at the&nbsp;U.S. embassy in Moscow and also as an English teacher, would be on U.S. soil by Tuesday night.
&#8220;President Trump, Steve Witkoff and the president&#8217;s advisors negotiated an exchange that serves as a show of good faith from the Russians and a sign we are moving in the right direction to end the brutal and terrible war in Ukraine,&#8221; he said in a statement, <a href="https://www.cbsnews.com/news/marc-fogel-released-russia-trump/">cited</a> by CBS News.
In what CNN <a href="https://www.cnn.com/2025/02/11/politics/marc-fogel-released-russia-trump/index.html">referred</a> to as an extraordinary move, Witkoff personally went to Russia to bring back Fogel, the statement indicated. There has been no known high-level U.S. travel to Russia since the start of the war in Ukraine in February 2022.
"By tonight, Marc Fogel will be on American soil and reunited with his family and loved ones thanks to President Trump's leadership," Waltz's statement said.
Fogel's family <a href="https://www.cnn.com/2025/02/11/politics/marc-fogel-released-russia-trump/index.html">said</a> Tuesday they "are beyond grateful, relieved, and overwhelmed that after more than three years of detention" he is coming home.
"Thanks to the unwavering leadership of President Trump, Marc will soon be back on American soil, free where he belongs," Jane, Ethan and Sam Fogel said in a statement.
Fogel was a legal medical marijuana patient in Pennsylvania where he used cannabis as an alternative to opioids for chronic pain following spinal surgery.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43639754/ukraine-floats-land-swap-with-russia-as-trump-signals-peace-push">Ukraine Floats Land Swap With Russia As Trump Signals Peace Push</a></li>
</ul>
Photo: Melnikov Dmitriy/Shutterstock.com

Cannabis

Government

Global

Trump Administration Secures Release Of Cannabis Prisoner Marc Fogel From 14-Year Russian Sentence

SWTX

SpringWorks Secures FDA Approval Of GOMEKLI For Treatment Of Adult And Pediatric Patients With NF1-PN

Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) sees FY2025 sales of $285.000 million-$288.000 million vs $285.99 million analyst estimate.

Guidance

SMWB

Similarweb Sees FY2025 Sales $285.000M-$288.000M vs $285.99M Est

Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) sees Q1 sales of $66.000 million-$66.500 million vs $67.36 million analyst estimate.

Similarweb Sees Q1 Sales $66.000M-$66.500M vs $67.36M Est

Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.04 by 25 percent. This is a 50 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $65.59 million which beat the analyst consensus estimate of $65.42 million by 0.25 percent. This is a 15.56 percent increase over sales of $56.76 million the same period last year.

Earnings Misses

Similarweb Q4 Adj $0.03 Misses $0.04 Estimate, Sales $65.59M Beat $65.42M Estimate

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price target at ...

Prelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy Rating

Prelude Therapeutics GAAP EPS of -$0.43, revenue of $3M

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a pric...

Prelude Therapeutics (PRLD) Gets a Sell from Morgan Stanley

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price targ...

Prelude Therapeutics (PRLD) Receives a Sell from Barclays

Warning: PRLD is at high risk of performing badly

Prelude Therapeutics, Inc. ( ($PRLD) ) has released its Q3 earnings. Here is a breakdown of the information Prelude Therapeutics, Inc. presented to...

Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report), with a pric...

Prelude Therapeutics: Promising Clinical Advancements and Strong Financial Position Drive Buy Rating

Morgan Stanley analyst Jeffrey Hung maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report) yesterday. The company's shares close...

B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers on t...

Foghorn Therapeutics initiated with a Buy at B. Riley

The latest update is out from Prelude Therapeutics ( ($PRLD) ). Prelude Therapeutics has appointed Bryant D. Lim as the permanent Chief Financial O...

Prelude Therapeutics Appoints Bryant D. Lim as CFO

FHTX

Health Care

Press Releases

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Comments

Prelude Therapeutics

Interés en corto

Prelude Therapeutics (NASDAQ:PRLD) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL